Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: History and new QSAR perspectives

Medicinal Research Reviews

Volumn 32, Issue 1, 2012, Pages 1-165

  Pontiki, Eleni ^a   Hadjipavlou Litina, Dimitra ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Drug design; Electronic parameters; Histone deacetylase inhibitors; Lipophilicity; QSAR; Sirtuins; Steric factors

Indexed keywords

3 [(3 CHOLAMIDOPROPYL)DIMETHYLAMMONIO] 1 PROPANESULFONIC ACID; 4 PHENYLBUTYRIC ACID; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; DEPSIPEPTIDE; ENTINOSTAT; EX 527; HETEROCYCLIC KETONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; HYDROXAMIC ACID DERIVATIVE; INDOLE DERIVATIVE; N HYDROXY 3 PHENYL 2 PROPENAMIDE; NF 675; NICOTINAMIDE; OXAMFLATIN; PHENYLALANINE; PHOSPHOTRANSFERASE INHIBITOR; PIVALOYLOXYMETHYL BUTYRATE; ROMIDEPSIN; SIRTINOL; SIRTUIN 1; SIRTUIN 2; SPLITOMYCIN; SUCCINIMIDE; SULFONAMIDE; SURFACTIN; TACEDINALINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; URACIL; VALPROIC ACID; VORINOSTAT; ZINC;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOASSAY; CANCER THERAPY; CELL DIFFERENTIATION; CELL GROWTH; DRUG DESIGN; DRUG SCREENING; HUMAN; LIPOPHILICITY; PROTEIN MOTIF; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BENZAMIDES; FATTY ACIDS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROGEN BONDING; HYDROXAMIC ACIDS; INDOLES; NAPHTHALENES; NAPHTHOLS; NIACINAMIDE; PEPTIDES, CYCLIC; PHENYLBUTYRATES; PHYSICOCHEMICAL PHENOMENA; PYRONES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84055190790     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20200     Document Type: Article

References (212)

1. Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 2008;14:505-528.
2. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Disc 2006;5:769-784.
3. Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: From bench to clinic. J Med Chem 2008;51:1505-1529.
4. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-1080.
5. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001;1:194-202.
6. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
7. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005;40:1-13.
8. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R. Histone deacetylation in epigenetics: An attractive target for anticancer therapy. Med Res Rev 2005;25:261-309.
9. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharm 2003;3:344-351.
10. Roth SY, Denu JM, Allis DC. Histone acetyltransferases. Annu Rev Biochem 2001;70:81-120.
11. Hodawadekar SC, Marmorstein R. Chemistry of acetyl transfer by histone modifying enzymes: Structure, mechanism and implications for effector design. Oncogene 2007;26:5528-5240.
12. Mai A. The therapeutic uses of chromatin-modifying agents. Expert Opin Ther Targets 2007;11:835-851.
13. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007;26:5541-5552.
14. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkühler C. HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics. Cell Res 2007;17:195-211.
15. De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB. Histone deacetylases (HDACs): Characterization of the classical HDAC family. J Biochem 2003;370:737-749.
16. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004;73:417-435.
17. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-3993.
18. Marks PA, Dokmanovich M. Histone deacetylase inhibitors: Discovery and development as anticancer agents. Expert Opin Investig Drugs 2005;14:1495-1511.
19. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol 2004;338:17-31.
20. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 2006;126:257-268.
21. Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, Barker J, Yau WT, Amouzegh P, Flegg A, Hamelin E, Thomas RJ, Kates M, Jones S, Navia MA, Saunders JO, DiStefano PS, Curtis R. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005;48:8045-8054.
22. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007;16:659-678.
23. Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002;277:25748-25755.
24. Sanders BD, Jackson B, Marmorstein R. Structural basis for sirtuin function: What we know and what we don't. Biochim Biophys Acta 2009; Epub ahead of print.
25. Dutnall RN, Pillus L. Deciphering NAD-dependent deacetylases. Cell 2001;105:161-164.
26. Marks PM, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004;91:137-168.
27. Kyrylenko S, Kyrylenko O, Suuronen T, Salminem A. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell Mol Life Sci 2003;60:1990-1997.
28. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 2007;5:981-989.
29. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-193.
30. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46:5097-5116.
31. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (Camb) 2004;12:1325-1334.
32. Docmanovich M, Marks PA. Prospects: Histone deacetylase inhibitors. J Cell Biochem 2005;96:293-304.
33. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-17179.
34. Tsuji N, Kobayashi K, Nagashima Y, Wakisaka K, Koizumi J. A new antifungal antibiotic, trichostatin. J Antibiot 1976;29:1-6.
35. Kelly WK, O' Conor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks P A, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931.
36. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, Kelly WK. Potential role of histone deacetylase inhibitors in mesothelioma: Clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006;7:257-261.
37. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-39.
38. Rosato RR, Grant S. Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 2004;13:21-38.
39. Marson CM, Mahadevan T, Dines J, Sengmany S, Morrell JM, Alao JP, Joel SP, Vigushin DM, Charles Coombes R. Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Biorg Med Chem Lett 2007;17:136-141.
40. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 2001;98:87-92.
41. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62:4916-4921.
42. Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 2001;61:4459-4466.
43. Colletti SL, Myers RW, Darkin-Rattray SJ, Gurnett AM, Dulski PM, Galuska S, Allocco JJ, Ayer MB, Li C, Lim J, Crumley TM, Cannova C, Schmatz DM, Wyvratt MJ, Fisher MH, Meinke PT. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure-activity relationships of apicidin. Part 1. Bioorg Med Chem Lett 2001;11:107-111.
44. Rephaeli A, Zhuk R, Nudelman A. Prodrugs of butyric acid from bench to bedside: Synthetic design, mechanisms of action, and clinical applications. Drug Dev Res 2000;50:379-391.
45. Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M, LoRusso PM. Chronic oral administration of CI-994: A phase 1 study. Invest New Drugs 2001;19:1-11.
46. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999;96:4592-4597.
47. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, Thiele CJ. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62:6108-6115.
48. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63:3637-3645.
49. Eyupoglu IY, Hahnen E, Trankle C, Savaskan NE, Siebzehnrübl FA, Buslei R, Lemke D, Wick W, Fahlbusch R, Blümcke I. Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 2006;5:1248-1255.
50. Avalos JL, Bever KM, Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: Altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell 2005;17:855-868.
51. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 2001;98:15113-15118.
52. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y, Kaneki M. Sirt1 inhibitor, sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006;25:176-185.
53. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, Depinho RA, Gu Y, Simon JA, Bedalov A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006;66:4368-4377.
54. Olaharski AJ, Rine J, Marshall BL, Babiarz J, Zhang L, Verdin E, Smith MT. The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet 2005;1:e77.
55. Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, Barker J, Yau WT, Amouzegh P, Flegg A, Hamelin E, Thomas RJ, Kates M, Jones S, Navia MA, Saunders JO, DiStefano PS, Curtis R. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005;48:8045-8054.
56. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002;277:45099-45107.
57. Sanders BD, Jackson B, Brent M, Taylor AM, Dang W, Berger SL, Schreiber SL, Howitz K, Marmorstein R. Identification and characterization of novel sirtuin inhibitor scaffolds. Bioorg Med Chem 2009;17:7031-7041.
58. Tervo AJ, Kyrylenko S, Niskanen P, Salminen A, Leppanen J, Nyronen TH, Jarvinen T, Poso A. An in silico approach to discovering novel inhibitors of human sirtuin type 2. J Med Chem 2004;47:6292-6298.
59. Suzuki T, Imai K, Nakagawa H, Miyata N. 2-Anilinobenzamides as SIRT inhibitors. Chem Med Chem 2006;1:1059-1062.
60. Posakony J, Hirao M, Stevens S, Simon JA, Bedalov A. Inhibitors of Sir2: Evaluation of Splitomicin Analogs. J Med Chem 2004;47:2635-2644.
61. Neugebauer RC, Uchiechowska U, Meier R, Hruby H, Valkov V, Verdin E, Sippl W, Jung M. Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J Med Chem 2008;51:1203-1213.
62. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001;276:38837-38843.
63. Mai A, Massa S, Lavu S, Pezzi R, Simeoni S, Ragno R, Mariotti FR, Chiani F, Camilloni G, Sinclair DA. Design, synthesis, and biological evaluation of sirtinol analogs as class III histone/protein deacetylase (sirtuin) inhibitors. J Med Chem 2005;48:7789-7795.
64. Lara E, Mai A, Calvanese V, Altucci L, Lopez-Nieva P, Martinez-Chantar ML, Varela-Rey M, Rotili D, Nebbioso A, Ropero S, Montoya G, Oyarzabal J, Velasco S, Serrano M, Witt M, Villar-Garea A, Inhof A, Mato JM, Esteller M, Fraga MF. Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2009;28:781-791.
65. Trapp J, Jochum A, Meier R, Saunders L, Marshall B, Kunick C, Verdin E, Goekjian PG, Sippl W, Jung M. Adenosine mimetics as inhibitors of NAD1-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem 2006;49:7307-7316.
66. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191-196.
67. +-dependent deacetylase. Mol Biochem Parasitol 2008;158:139-151.
68. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008;13:454-463.
69. Asaba T, Suzuki T, Ueda R, Tsumoto H, Nakagawa H, Miyata NJ. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate. Am Chem Soc 2009;131:6989-6996.
70. Suzuki T, Asaba T, Imai E, Tsumoto H, Nakagawa H, Miyata N. Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine. Bioorg Med Chem Lett. 2009;19:5670-5672.
71. Chou KC. Review: Structural bioinformatics and its impact to biomedical science. Cur Med Chem 2004;11:2105-2134.
72. Chou KC. Molecular therapeutic target for type-2 diabetes. J Prot Res 2004;3:1284-1288.
73. Li Y, Wei DQ, Gao WN, Gao H, Liu BN, Huang CJ, Xu WR, Liu DK, Chen HF, Chou KC. Computational approach to drug design for oxazolidinones as antibacterial agents. Med Chem 2007;3:576-582.
74. Prado-Prado FJ, de la Vega OM, Uriarte E, Ubeira FM, Chou KC, Gonzalez-Diaz H. Unified QSAR approach to antimicrobials. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg Med Chem 2009; 17:569-575.
75. Chou KC. Modelling extracellular domains of GABA-A receptors: Subtypes 1, 2, 3, and 5. Biochem Biophys Res Comm 2004;316:636-642.
76. Chou KC. Insights from modelling the 3D structure of the extracellular domain of alpha7 nicotinic acetylcholine receptor. Biochem Biophys Res Comm 2004;319:433-438.
77. Huang RB, Du QS, Wang CH, Chou KC. An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochem Biophys Res Comm 2008;377:1243-1247.
78. Sirois S, Wei DQ, Du QS, Chou KC. Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. J Chem Inf Comput Sci 2004;44:1111-1122.
79. Chou KC. Energy-optimized structure of antifreeze protein and its binding mechanism. J Mol Biol 1992;223:509-517.
80. Du QS, Mezey PG, Chou KC. Heuristic molecular lipophilicity potential (HMLP): A 2D-QSAR study to LADH of molecular family pyrazole and derivatives. J Comput Chem 2005;26:461-470.
81. Du QS, Huang RB, Wei YT, Du LQ, Chou KC. Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR). J Comput Chem 2008;29:211-219.
82. Du QS, Huang RB, Chou KC. Review: Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr Protein Pept Sci 2008;9:248-259.
83. Gonzalez-Diaz H, Gonzalez-Diaz Y, Santana L, Ubeira FM, Uriarte E. Proteomics, networks, and connectivity indices. Proteomics 2008;8:750-778.
84. Chou KC, Shen HB. Cell-PLoc: A package of web-servers for predicting subcellular localization of proteins in various organisms. Nat Prot 2008;3:153-162.
85. Chou KC, Shen HB. Hum-PLoc: A novel ensemble classifier for predicting human protein subcellular localization. BBRC 2006;347:150-157.
86. Chou KC, Shen HB. MemType-2L: A Web server for predicting membrane proteins and their types by incorporating evolution information through Pse-PSSM. Biochem Biophys Res Comm 2007;360:339-345.
87. Shen HB, Chou KC. EzyPred: A top-down approach for predicting enzyme functional classes and subclasses. Biochem Biophys Res Comm 2007;364:53-59.
88. Chou KC, Elrod DW. Bioinformatical analysis of G-protein-coupled receptors. J Proteome Res 2002;1:429-433.
89. Xiao X, Wang P, Chou KC. GPCR-CA: A cellular automaton image approach for predicting G-protein-coupled receptor functional classes. J Comput Chem 2009;30:1414-1423.
90. Chou KC, Shen HB. ProtIdent: A web server for identifying proteases and their types by fusing functional domain and sequential evolution information. Biochem Biophys Res Comm 2008;376:321-325.
91. Shen HB, Chou KC. Identification of proteases and their types. Anal Biochem 2009;385:153-160.
92. Chou KC. A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins. J Biol Chem 1993;268:16938-16948.
93. Chou KC. Review: Prediction of HIV protease cleavage sites in proteins. Anal Biochem 1996;233:1-14.
94. Chou KC, Shen HB. Signal-CF: A subsite-coupled and window-fusing approach for predicting signal peptides. Biochem Biophys Res Comm 2007;357:633-640.
95. Shen HB, Chou KC. Signal-3L: A 3-layer approach for predicting signal peptide. Biochem Biophys Res Comm 2007;363:297-303.
96. Xie A, Liao C, Li Z, Ning Z, Hu W, Lu X, Shi L, Zhou J. Quantitative structure-activity relationship study of histone deacetylase inhibitors. Curr Med Chem Anticancer Agents 2004;4:273-299.
97. Wang DF, Wiest O, Helquist P, Lan-Hargest HY, Wiech NL. QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. Bioorg Med Chem Lett 2004;14:707-711.
98. Guo Y, Xiao J, Guo Z, Chu F, Cheng Y, Wu S. Exploration of a binding mode of indole amide analogs as potent histone deacetylase inhibitors and 3D-QSAR analyses. Bioorg Med Chem Lett 2005;13:5424-5434.
99. Ragno R, Simeoni S, Valente S, Massa S, Mai A. 3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compounds. J Chem Inf Model 2006;46:1420-1430.
100. Juvale DC, Kulkarni VV, Deokar HH, Wagh NK, Padhye SB, Kulkami VM. 3D-QSAR of histone deacetylase inhibitors: Hydroxamate analogs. Org Biomol Chem 2006;4:2858-2868.
101. Katritzky AR, Slavov SH, Dobchev DA, Karelson M. Comparison between 2D and 3D-QSAR approaches to correlate inhibitor activity for a series of indole amide hydroxamic acids. QSAR Comb Sci 2007;3:333-345.
102. Dai Y, Guo Y, Guo J, Pease LJ, Li J, Marcotte PA, Glaser KB, Tapang P, Albert D H, Richardson PL, Davidsen SK, Michaelides MR. Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. Bioorg Med Chem Lett 2003;13:1897-1901.
103. Dessalew N. QSAR study on aminophenylbenzamides and acrylamides as histone deacetylase inhibitors: An insight into the structural basis of antiproliferative activity. Med Chem Res 2007;16:449-460.
104. Moradei O, Leit S, Zhou N, Frechette F, Bouchain C, Woo HS, Paguin I, Raeppel S, Frechette S, Vaisburg A, Fournal M, Kalita A, Lu A, Claude M, Bourget T, Yan P, Liu J, Li Z, Rahil J, Macleod RA, Besterman MJ, Delorme D. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogs: Novel classes of histone deacetylase inhibitors. Bioorg Med Chem Lett 2006;16:4048-4052.
105. Ragno R, Simeoni S, Rotili D, Caroli A, Botta G, Brosch G, Massa S, Mai A. Class II-selective histone deacetylase inhibitors. Part 2: Alignment-independent GRIND 3-D QSAR, homology and docking studies. Eur J Med Chem 2008;43:621-632.
106. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem 2005;48:3344-3353.
107. Chen Y, Jiang YJ, Zhou JW, Yu QC, You QD. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. J Mol Graph Model 2008;26:1160-1168.
108. Kozikowski AP, Chen Y, Gaysin AM, Savoy DN, Billadeau DD, Kim KH. Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth. Chem Med Chem 2008;3:487-501.
109. oct from structures. Chem Rev 1993;93:1281-1306.
110. Hansch C, Leo AJ, Taft WR. A survey of hammett substituent constants and resonance and field parameters. Chem Rev 1991;91:165-195.
111. Unger SH, Hansch C. Quantitative models of steric effects. Prog Phys Org Chem 1976;12:91-114.
112. Hansch C, Leo A. J Exploring QSAR: Fundamentals and applications in chemistry and Biology. Washington, DC: American Chemical Society; 1995.
113. Hansch C, Leo AJ, Hoekman D. Exploring QSAR: Hydrophobic, electronic and steric constants. Washington, DC: American Chemical Society; 1995.
114. Silippo C, Vittoria A. Comprehensive medicinal chemistry. In: Hansch C, Sammes PG, Taylor JB, editors. Three dimensional structure of drugs, Vol. 4. New York: CA Ramsden Pergamon Press; 1990, Ch. 18.4, 153.
115. Verloop A. The Sterimol approach to drug design. New York: Marcell Dekker, 1987.
116. BioByte Corporation, C-QSAR database, 201 W Fourth str., Suite {music sharp sign} 204, Claremont, CA 91711 -4707, USA.
117. Kiers Henk AL, Smilde Age K. A comparison of various methods of multivarate regression with highly collinear variables. Stat Methods Appl 2007;16:193-228.
118. Abraham M, McGogan JC. The use of characteristic volumes to measure cavity terms in reversed phase liquid chromatography. Chromatographia 1987;23:243-246.
119. Verloop A, Hoogenstraaten W, Tipker J. In: Ariens EJ, editor. Drug design, Vol. VII. New York, Academic Press: 1976; p 165.
120. Cramer RD, Bruce JD, Patterson DE, Frank IE. Crossvalidation, bootstrapping and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct-Act Relat 1988;7:18-22.
121. Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Model 2002;20:269-276.
122. Pogliani L. Modeling with Special Descriptors Derived from a Medium-Sized Set of Connectivity Indices. J Phys Chem 1996;100:18065-18077.
123. Agrawal VK, Singh J, Khadikar PV, Supuran CT. QSAR study on topically acting sulfonamides incorporating GABA moieties: A molecular connectivity approach. Bioorg Med Chem Lett 2006;16:2044-2051.
124. Sujuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, Yamashita T, Nakanishi O. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999;42:3001-3003.
125. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999;96:4592-4597.
126. Jung M, Brosch G, Kölle D, Scherf H, Gerhäuser C, Loidl P. Amide analogs of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem 1999;42:4669-4679.
127. Lavoie R, Bouchain G, Frechette S, Woo SH, Abou Khalil E, Leit S, Fournel M, Yan PT, Trachy-Bourget MC, Beaulieu C, Li Z, Besterman J, Delorme D. Design and synthesis of a novel class of histone deacetylase inhibitors. Biorg Med Chem Lett 2001;11:2847-2850.
128. Curtin ML, Garland RB, Heyman HR, Frey RR, Michaelides MR, Li J, Pease LJ, Glaser KB, Marcotte PA, Davidsen SK. Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC). Bioorg Med Chem Lett 2002;12:2919-2923.
129. Sternson SM, Wong JC, Grozinger CM, Schreiber SL. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett 2001;3:4239-4242.
130. Woo SH, Frechette S, Abou Khalil E, Bouchain G, Vaisburg A, Bernstein N, Moradei O, Leit S, Allan M, Fournel M, Trachy-Bourget MC, Li Z, Besterman JM, Delorme D. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J Med Chem 2002;45:2877-2885.
131. Wittich S, Scherf H, Xie C, Brosch G, Loidl P, Gerhaüser C, Jung M. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: In vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J Med Chem 2002;45:3296-3309.
132. Wada CK, Frey RR, Ji Z, Curtin ML, Garland RB, Holms JH, Li J, Pease LJ, Guo J, Glaser KB, Marcotte PA, Richardson PL, Murphy SS, Bouska JJ, Tapang P, Magoc TJ, Albert DH, Davidsen SK, Michaelides MR. Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett 2003;13:3331-3335.
133. Gelb MH, Svaren JP, Abeles RH. Fluoro ketone inhibitors of hydrolytic enzymes. Biochemistry 1985;24:1813-1817.
134. Vasudevan A, Ji Z, Frey RR, Wada CK, Steinman D, Heyman HR, Guo Y, Curtin ML, Guo J, Li J, Pease L, Glaser KB, Marcotte PA, Bouska JJ, Davidsen SK, Michaelides MR. Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 2003;13:3909-3913.
135. Bouchain G, Leit S, Frechette S, Khalil EA, Lavoie R, Moradei O, Woo SH, Fournel M, Yan PT, Kalita A, Trachy-Bourget MC, Beaulieu C, Li Z, Robert MF, MacLeod AR, Besterman JM, Delorme D. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. J Med Chem 2003;46:820-830.
136. Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl) [2-(1H-indol-3-yl) ethyl] amino] methyl]phenyl]-2 propenamide (NVP-LAQ824). J Med Chem 2003;46:4609-4624.
137. Mai A, Massa S, Pezzi R, Rotili D, Loidl P, Brosch G. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J Med Chem 2003;46:4826-4829.
138. Kim DK, Lee JY, Kim JS, Ryu JH, Choi JY, Lee JW, Im GJ, Kim TK, Seo JW, Park HJ, Yoo J, Park JH, Kim TY, Bang YJ. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. J Med Chem 2003;46:5745-5751.
139. Fournel M, Trachy-Bourget MC, Yan PT, Kalita A, Bonfils C, Beaulieu C, Frechette S, Leit S, Abou-Khalil E, Woo SH, Delorme D, MacLeod AR, Besterman JM, Li Z. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 2002;62:4325-4330.
140. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998;95:3003-3007.
141. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999;18:2461-2470.
142. Jung M, Hoffmann K, Brosch G, Loidl P. Analogs of trichostatin a and trapoxin B as histone deacetylase inhibitors. Bioorg Med Chem Lett 1997;7:1655-1658.
143. Frey RR, Wada CK, Garland RB, Curtin ML, Michaelides MR, Li J, Pease LJ, Glaser KB, Marcotte PA, Bouska JJ, Murphy SS, Davidsen SK. Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 2002;12:3443-3447.
144. Massa S, Mai A, Sbardella G, Esposito M, Ragno R, Loidl P, Brosch G. 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J Med Chem 2001;44:2069-2072.
145. Uesato S, Kitagawa M, Nagaoka Y, Maeda T, Kuwajima H, Yamori T. Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. Bioorg Med Chem Lett 2002;12:1347-1349.
146. Vaisburg A, Bernstein N, Frechette S, Allan M, Abou-Khalil E, Leit S, Moradei O, Bouchain G, Wang J, Woo SH, Fournel M, Yan PT, Trachy-Bourget MC, Kalita A, Beaulieu C, Li Z, MacLeod AR, Besterman JM, Delorme D. (2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. Bioorg Med Chem Lett 2004;14:283-287.
147. Glaser KB, Li J, Pease LJ, Staver MJ, Marcotte PA, Guo J, Frey RR, Garland RB, Heyman HR, Wada CK, Vasudevan A, Michaelides MR, Davidsen SK, Curtin ML. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem Biophys Res Commun 2004;325:683-690.
148. Wu TY, Hassig C, Wu Y, Ding S, Schultz PG. Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. Bioorg Med Chem Lett 2004;14:449-453.
149. Maeda T, Nagaoka Y, Kuwajima H, Seno C, Maruyama S, Kurotaki M, Uesato S. Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities. Bioorg Med Chem 2004;12:4351-4360.
150. Mori H, Sakamoto K, Tsurumi Y, Takase S, Hino M. WO 00/21979. Chem Abstr 2000;132:288796.
151. 2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem 2004;47:467-474.
152. Newmark HL, Young CW. Butyrate and phenylacetate as differentiating agents: Practical problems and opportunities. J Cell Biochem Suppl 1995;22:247-253.
153. Lea MA, Tulsyan N. Discordant effects of butyrate analogs on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res 1995;15:879-883.
154. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1982;42:65-82.
155. Phiel CJ, Gabbeta V, Parsons LM, Rothblat D, Harvey RP, McHugh KM. Differential binding of an SRF/NK-2/MEF2 transcription factor complex in normal versus neoplastic smooth muscle tissues. J Biol Chem 2001;276:34637-34650.
156. Mai A, Massa S, Cerbara I, Valente S, Ragno R, Bottoni P, Scatena R, Loidl P, Brosch G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity. J Med Chem 2004;47:1098-1109.
157. Brosch G, Lusser A, Goralik-Schramel M, Loidl P. Purification and characterization of a high molecular weight histone deacetylase complex (HD2) of maize embryos. Biochemistry 1996;35:15907-15914.
158. Kölle D, Brosch G, Lechner T, Lusser A, Loidl P. Biochemical methods for analysis of histone deacetylases. Methods 1998;15:323-331.
159. Shinji C, Nakamura T, Maeda S, Yoshida M, Hashimoto Y, Miyachi H. Design and synthesis of phthalimide-type histone deacetylase inhibitors. Bioorg Med Chem Lett 2005;15:4427-4431.
160. Mai A, Massa S, Rotili D, Pezzi R, Bottoni P, Scatena R, Meraner J, Brosch G. Exploring the connection unit in the HDAC inhibitor pharmacophore model: Novel uracil-based hydroxamates. Bioorg Med Chem Lett 2005;15:4656-4561.
161. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkühler C, Di Marco S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004;101:15064-15069.
162. Dai Y, Guo Y, Curtin ML, Li J, Pease LJ, Guo J, Marcotte PA, Glaser KB, Davidsen SK, Michaelides MR. A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett 2003;13:3817-3820.
163. Mai A, Massa S, Ragno R, Cerbara I, Jesacher F, Loidl P, Brosch G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. J Med Chem 2003;46:512-524.
164. Massa S, Mai A, Sbardella G, Esposito M, Ragno R, Loidl P, Brosch G. 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J Med Chem 2001;44:2069-2072.
165. Mai A, Massa S, Ragno R, Esposito M, Sbardella G, Nocca G, Scatena R, Jesacher F, Loidl P, Brosch G. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: A new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. J Med Chem 2002;45:1778-1784.
166. Ragno R, Mai A, Massa S, Cerbara I, Valente S, Bottoni P, Scatena R, Jesacher F, Loidl P, Brosch G. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. J Med Chem 2004;47:1351-1359.
167. Mai A, Massa S, Pezzi R, Valente S, Loidl P, Brosch G. Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors. J Med Chem 2005;1:245-254.
168. Angibaud P, Arts J, Van Emelen K, Poncelet V, Pilatte I, Roux B, Van Brandt S, Verdonck M, De Winter H, Ten Holte P, Marien A, Floren W, Janssens B, Van Dun J, Aerts A, Van Gompel J, Gaurrand S, Queguiner L, Argoullon JM, Van Hijfte L, Freyne E, Janicot M. Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors. Eur J Med Chem 2005;40:597-606.
169. Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, Nakagawa H, Miyata N. Novel inhibitors of human histone deacetylases: Design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem 2005;48:1019-1032.
170. Christianson DW, Lipscomb WN. X-ray crystallographic investigation of substrate binding to carboxypeptidase A at subzero temperature. Proc Natl Acad Sci USA 1986;83:7568-7572.
171. Christianson DW, David PR, Lipscomb WN. Mechanism of carboxypeptidase A: Hydra ion of a ketonic substrate analog.Proc Natl Acad Sci USA 1987;84:1512-1515.
172. Moree WJ, Van der Marel GA, Liskamp RMJ. Peptides containing a sulfinamide or a sulfonamide moiety: New transition-state analogs. Tetrahedron Lett 1991;32:409-412.
173. Moradei O, Leit S, Zhou N, Fréchette S, Paquin I, Raeppel S, Gaudette F, Bouchain G, Woo SH, Vaisburg A, Fournel M, Kalita A, Lu A, Trachy-Bourget MC, Yan PT, Liu J, Li Z, Rahil J, MacLeod AR, Besterman JM, Delorme D. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogs: novel classes of histone deacetylase inhibitors. Bioorg Med Chem Lett 2006;16:4048-4052.
174. Charrier C, Bertrand P, Gesson JP, Roche J. Synthesis of rigid trichostatin A analogs as HDAC inhibitors. Bioorg Med Chem Lett 2006;16:5339-5344.
175. Koseki K, Mori K. Synthesis of trichostatin a, a potent differentiation inducer of friend leukemic cells, and its antipode. Tetrahedron 1988;44:6013-6020.
176. Hosokawa S, Ogura T, Togashi H, Tatsuta K. The first total synthesis of trichostatin D. Tetrahedron Lett 2005;46:333-337.
177. Elaut G, Török G, Vinken M, Laus G, Papeleu P, Tourwe D, Rogiers V. Major phase I biotransformation pathways of Trichostatin a in rat hepatocytes and in rat and human liver microsomes. Drug Metab Dispos 2002;30:1320-1328.
178. Chem 3 D tools (calculation from Mopac, Am1 method, closed shield).
179. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-458.
180. Jones P, Altamura S, Chakravarty PK, Cecchetti O, De Francesco R, Gallinari P, Ingenito R, Meinke PT, Petrocchi A, Rowley M, Scarpelli R, Serafini S, Steinkühler C. A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg Med Chem Lett 2006;16:5948-5952.
181. Shinji C, Maeda S, Imai K, Yoshida M, Hashimoto Y, Miyachi H. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Bioorg Med Chem 2006;14:7625-7651.
182. Miyachi H, Azuma A, Ogasawara A, Uchimura E, Watanabe N, Kobayashi Y, Kato F, Kato M, Hashimoto Y. Novel biological response modifiers: Phthalimides with tumor necrosis factor-alpha production-regulating activity. J Med Chem 1997;40:2858-2865.
183. Miyachi H, Ogasawara A, Azuma A, Hashimoto Y. Tumor necrosis factor-alpha production-inhibiting activity of phthalimide analogs on human leukemia THP-1 cells and a structure-activity relationship study. Bioorg Med Chem 1997;5:2095-2102.
184. Miyachi H, Azuma A, Kitamoto T, Hayashi K, Kato S, Koga M, Sato B, Hashimoto Y. Potent novel nonsteroidal androgen antagonists with a phthalimide skeleton. Bioorg Med Chem Lett 1997;7:1483-1488.
185. Miyachi H, Kato M, Kato F, Hashimoto Y. Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton. J Med Chem 1998;41:263-265.
186. Nagaoka Y, Maeda T, Kawai Y, Nakashima D, Oikawa T, Shimoke K, Ikeuchi T, Kuwajima H, Uesato S. Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: Hydrophilic hydroxamates and 2-aminobenzamide containing derivatives. Eur J Med Chem 2006;41:697-708.
187. Bieliauskas AV, Weerasinghe SVW, Pflum MKH. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bioorg Med Chem Lett 2007;17:2216-2219.
188. Belvedere S, Witter DJ, Yan J, Secrist P, Richon V, Miller TA. Aminosuberoyl hydroxamic acids (ASHAs): A potent new class of HDAC inhibitors. Bioorg Med Chem Lett 2007;17:3969-3971.
189. Shivashimpi GM, Amagai S, Kato T, Nishino N, Maeda S, Nishino TG, Yoshida M. Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem 2007;15:7830-7839.
190. Kim HM, Ryu DK, Choi Y, Park BY, Lee K, Han SB, Lee CY, Kang MR, Kang JS, Boovanahalli SK, Park SK, Han JW, Chun TG, Lee HY, Nam KY, Choi EH, Han G. Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors. J Med Chem 2007;50:2737-2741.
191. Mahboobi S, Sellmer A, Höcher H, Garhammer C, Pongratz H, Maier T, Ciossek T, Beckers T. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors. J Med Chem 2007;50:4405-4418.
192. Price S, Bordogna W, Braganza R, Bull RJ, Dyke HJ, Gardan S, Gill M, Harris NV, Heald RA, van den Heuvel M, Lockey PM, Lloyd J, Molina AG, Roach AG, Roussel F, Sutton JM, White AB. Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 2007;17:363-369.
193. Moradei OM, Mallais TC, Frechette S, Paquin I, Tessier PE, Leit SM, Fournel M, Bonfils C, Trachy-Bourget MC, Liu J, Yan TP, Lu AH, Rahil J, Wang J, Lefebvre S, Li Z, Vaisburg AF, Besterman JM. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem 2007;50:5543-5546.
194. Andrews DM, Gibson KM, Graham MA, Matusiak ZS, Roberts CA, Stokes ESE, Brady MC, Chresta CM. Design and campaign synthesis of pyridine-based histone deacetylase inhibitors. Bioorg Med Chem 2008;18:2525-2529.
195. Stokes ESE, Roberts CA, Waring MJ. WO2003087057. Chem Abstr 2003;13:337995.
196. Mai A, Perrone A, Nebbioso A, Rotili D, Valente S, Tardugno M, Massa S, De Bellis F, Altucci L. Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: Histone deacetylase inhibition and in-cell activities. Bioorg Med Chem 2008;18:2530-2535.
197. Mai A, Massa S, Rotili D, Simeoni S, Ragno R, Botta G, Nebbioso A, Miceli M, Altucci L, Brosch G. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J Med Chem 2006;49:6046-6056.
198. Chen Y, Lopez-Sanchez M, Savoy DN, Billadeau DD, Dow GS, Kozikowski A P. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J Med Chem 2008;51:3437-3448.
199. Dehmel F, Weinbrenner S, Julius H, Ciossek T, Maier T, Stengel T, Fettis K, Burkhardt C, Wieland H, Beckers T. Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles. J Med Chem 2008;51:3985-4001.
200. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Disk 2007;6:21-22.
201. Wang DF, Wiest O, Helquist P, Lan-Hargest HY, Wiesch NL. On the function of the 14 A long internal cavity of histone deacetylase-like protein: Implications for the design of histone deacetylase inhibitors. J Med Chem 2004;47:3409-3417.
202. Selassie CD, Mekapati SB, Verma RP. QSAR: Then and now. Curr Top Med Chem 2002;2:1357-1379.
203. Hansch C, Kurup A, Garg R, Gao H. Chem-bioinformatics and QSAR: A Review of QSAR lacking positive hydrophobic terms. Chem Rev 2001;101:619-672.
204. Hansch C, Klein T. Molecular graphics and QSAR in the study of enzyme-ligand interactions. Acc Chem Res 1986;19:392-400.
205. Garg R, Kurup A, Mekapati SB, Hansch C. Cyclooxygenase (COX) inhibitors: A comparative QSAR Study. Chem Rev 2003;103:703-732.
206. Yoshida M, Matsuyama A, Komatsu Y, Nishino N. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 2003;10:2351-2358.
207. Yoshida M, Furumai R, Nishiyam M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001;48:S20-26.
208. Elaut G, Toylor G, Vinken M, Laus G, Papeleu P, Tourwe D, Rogiers V. Major phase I biotransforamation pathways of trichostatin A in rat hepatocytes and in rat and human liver microsomes. Drug Metab Dispos 2002;30:1320-1328.
209. Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, Coombes RC, Vigushin DM. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos 2004;32:1132-1138.
210. Hobdy E, Murren J. AN-9 Titan. Curr Opin Invest Drugs 2004;5:628-634.
211. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721-728.
212. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG. Anti-tumor activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999;80:1252-1258.